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ABSTRACT Zoonotic influenza H7 viral infections have a case fatality rate of about
40%. Currently, no or limited human to human spread has occurred, but we may be
facing a severe pandemic threat if the virus acquires the ability to transmit between
humans. Novel vaccines that can be rapidly produced for global distribution are ur-
gently needed, and DNA vaccines may be the only type of vaccine that allows for
the speed necessary to quench an emerging pandemic. Here, we constructed DNA
vaccines encoding the hemagglutinin (HA) from influenza A/chicken/Italy/13474/99
(H7N1). In order to increase the efficacy of DNA vaccination, HA was targeted to ei-
ther major histocompatibility complex class II molecules or chemokine receptors 1,
3, and 5 (CCR1/3/5) that are expressed on antigen-presenting cells (APC). A single
DNA vaccination with APC-targeted HA significantly increased antibody levels in sera
compared to nontargeted control vaccines. The antibodies were confirmed neutraliz-
ing in an H7 pseudotype-based neutralization assay. Furthermore, the APC-targeted
vaccines increased the levels of antigen-specific cytotoxic T cells, and a single DNA
vaccination could confer protection against a lethal challenge with influenza A/tur-
key/Italy/3889/1999 (H7N1) in mice. In conclusion, we have developed a vaccine that
rapidly could contribute protection against a pandemic threat from avian influenza.
IMPORTANCE Highly pathogenic avian influenza H7 constitute a pandemic threat
that can cause severe illness and death in infected individuals. Vaccination is the
main method of prophylaxis against influenza, but current vaccine strategies fall
short in a pandemic situation due to a prolonged production time and insufficient
production capabilities. In contrast, a DNA vaccine can be rapidly produced and de-
ployed to prevent the potential escalation of a highly pathogenic influenza pan-
demic. We here demonstrate that a single DNA delivery of hemagglutinin from an
H7 influenza could mediate full protection against a lethal challenge with H7N1 in-
fluenza in mice. Vaccine efficacy was contingent on targeting of the secreted vac-
cine protein to antigen-presenting cells.
KEYWORDS APC-targeting, DNA vaccine, avian viruses, hemagglutinin, influenza,
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Highly pathogenic avian influenza viruses (HPAIV) represent a potential pandemicthreat. As of June, 2017, the World Health Organization has reported a total of
1,533 laboratory-confirmed cases of human infection with avian influenza H7N9, with
a mortality rate of nearly 40% (1). A majority of these cases arose from zoonotic
transmissions at the human-animal interface, with limited human-to-human transmis-
sion. Viruses isolated from human cases, perhaps including secondary cases of human
transmissions, show only a few accumulated mutations in surface glycoproteins (2).
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Thus, it is difficult to predict the antigenic determinants of transmissibility that are
needed to break the zoonotic barrier and also how these would influence the viral
pathogenicity in humans (3). However, the human population is presently serologically
naive toward H7 influenza; therefore, the potential acquisition of mutations enabling
efficient human-to-human transmission could have a devastating effect.
Conventional vaccine design relies on an extensive surveillance system to determine
which influenza strains will be included in the next season’s influenza vaccine. The 2009
pandemic demonstrated that the development and vaccine production process could
be completed in about 6 months, which represents a best-case scenario (4). Both the
2009 H1N1 pandemic and the 2013 HPAIV H7N9 emergence in China (5) demonstrate
that it is difficult to predict which influenza strain will cause the next pandemic and that
conventional influenza vaccines are not sufficient in the face of a pandemic outbreak.
Novel vaccine formats that can rapidly be produced and quickly induce an immune
response upon a novel pandemic threat are urgently needed (6–8).
The multifaceted pathogenicity of HPAIV is maintained by two major determinants.
First, the hemagglutinin (HA) in HAPIV has a receptor binding preference for 2,3-linked
sialic acid that is abundant on the gut epithelia of aquatic birds (9). In humans, 2,3-
and 2,6-linked sialic acid receptors dominate in the lower and upper respiratory tract,
respectively. Efficient human-to-human transmission of influenza virus is dependent on
viral replication in the upper respiratory tract (10). The viral preference for 2,3-linked
sialic acid receptors thus represents a natural barrier for zoonotic and human-to-human
transmission with HPAIV (11). However, certain H7 isolates have been demonstrated to
bind both sialic acid receptors (12–14), forming a breach in the zoonotic barrier (15).
Second, HA in HPAIV have acquired a multibasic cleavage site (MBCS) (16–19). HA
cleavage is necessary for influenza infectivity, and where seasonal influenza HAs are
only cleaved by tissue-restricted proteases, HAPIV HAs can be cleaved by ubiquitous
cellular proteases. Thus, the potential pathogenicity of an HPAIV is enhanced since the
virus evades tissue-restricted replication (20–23).
DNA vaccines can be rapidly produced but are typically hampered by reduced
immunogenicity. Previously, we demonstrated that a single DNA vaccination with HA
from influenza H1N1 targeted to major histocompatibility complex class II (MHC-II)
molecules on antigen-presenting cells (APCs) confers sterilizing immunity against influenza
challenge in mice (24, 25). Furthermore, translation into larger animals confirmed the
increased immunogenicity after APC-targeting of antigen (26). In addition to MHC-II
targeting, chemokines are attractive targeting units due to the chemotactic recruitment
of, among others, dendritic cells (DCs), macrophages, and NK cells, and chemokines can
channel recruitment of internalized antigen to MHC-I and MHC-II presentation path-
ways (27–31). Here, we extended these experiments to vaccination against HPAIV H7.
After targeting of HA from A/chicken/Italy/13474/1999 (H7N1) or A/turkey/Italy/3889/
1999 (H7N1) to MHC-II molecules or chemokine receptors 1, 3, and 5 (CCR1/3/5)
expressed on APC, we demonstrate that a single DNA vaccination can confer protection
against a lethal H7N1 challenge in mice.
RESULTS
Construction and characterization of APC-targeted influenza vaccines. Previ-
ously, we demonstrated that a single DNA immunization with APC-targeted HA from
H1N1 influenzas provided protection against a lethal challenge in mice (23, 24). A key
feature of the vaccine was the bivalent display of antigens that were linked via a
dimerization unit containing the hinge region and CH3 from human IgG3 to targeting
units specific for receptors on APCs (Fig. 1A) (28, 32). Here, we inserted HA from
A/chicken/Italy/13474/99 (H7N1) (amino acids 19 to 536 [aa19-563]) into the same
vaccine format and targeted HA toward either chemokine receptors 1, 3, and 5
(CCR1/3/5), or MHC-II molecules (Fig. 1A). To target HA to MHC-II molecules, we used
a single-chain-variable fragment (scFv) that was specific for I-Ed (denoted MHCII-H7),
whereas the chemokine Mip1 was used for targeting of HA to CCR1/3/5 (denoted
Mip1-H7). As nontargeted controls, we constructed a vaccine where the APC-specific
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targeting unit was replaced with a scFv against the hapten Nip (denoted Nip-H7) and
a plasmid encoding only HA (denoted H7). In some experiments, we also used the
previously described MHC-II-targeted vaccine with HA from influenza A/Puerto Rico/
8/34 (H1N1) (24) to control for antigen specificity (denoted MHCII-H1).
Supernatants from 293E cells transiently transfected with the different vaccine
plasmids confirmed the appropriate size (Fig. 1B) and in vitro expression of the secreted
vaccine proteins (Fig. 1C). The nontargeted control, Nip-H7, exhibited an 2-fold-
higher protein expression level than the other vaccines, potentially providing a con-
centration dependent benefit for the in vivo DNA vaccinations. In order to verify
efficient binding of the vaccine proteins to APC, we assayed their binding profiles to
splenocytes (Fig. 1D). Vaccines targeting MHC-II molecules ligated B cells, macrophages,
and conventional DC1 and DC2, whereas CCR1/3/5-targeted vaccines ligated macro-
phages and conventional DC1. As expected, nontargeted control failed to ligate any of
the cell types investigated, and T cells were not bound by either of the constructs.
An intact multibasic cleavage site increases antibody responses. Conventional
production of vaccines against HPAIV depends on removal of the MBCS in order to
prevent disease and potential lethality embryonated hens’ eggs (4, 33). In contrast, this
is not a problem for the synthetic production of DNA vaccines. Therefore, we wanted
to compare the immunogenicities of APC-targeted H7 antigens with the intact or
deleted MBCS sequences, and we cloned an HA with a deleted MBCS into the
MHC-II-targeted vaccine format described above. The vaccine displaying the deleted
MBCS sequence was denoted MHCII-H7Δ (Fig. 2A).
The correct size and expression of MHCII-H7Δ was confirmed (Fig. 2C and D). Since
endogenous proteases in 293E cells will cleave H7 with intact MBCS (22), we observed
bands corresponding to cleavage of HA0 into HA1 (115 kDa, including the targeting
domain and dimerization unit) and HA2 (35 kDa) for MHCII-H7, but not for MHCII-
H7Δ (Fig. 2B and C). The in vitro expression levels of MHCII-H7Δ were slightly higher
than that of MHCII-H7 (Fig. 2D). Nevertheless, in vivo DNA vaccination of mice showed
that MHCII-H7 induced significantly higher IgG titers than did MHCII-H7Δ (Fig. 2E).
The difference was significant already 1 week postvaccination, and antibody levels
remained higher at least 4 weeks postvaccination. Taken together, the data suggest
that H7 with an intact MBCS could offer an immune-potentiating effect that is main-
tained when targeting of HA to MHC-II molecules in mice. Thus, further experiments
were performed with MHCII-H7.
Rapidly increased IgG levels after MHC-II-targeted vaccination. Since the rapid
induction of protection is crucial for pandemic prevention, mice were DNA vaccinated
only once, and antibody responses in serum were assessed for 5 weeks postvaccination.
FIG 1 Characterization of vaccine proteins. (A) Schematic illustration of a dimeric vaccine protein. The targeting units, either an scFv specific for mouse I-Ed
(MHCII), the chemokine MIP1 (Mip1), or a scFv specific for the hapten NIP (Nip; nontargeted control), are connected to HA via a dimerization unit
containing the hinge and CH3 domain from human IgG3. (B) Western blot of supernatants from 293E cells transfected with the indicated vaccine plasmids.
Molecular sizes and corresponding structures are indicated. (C) Vaccine proteins in supernatants from transiently transfected 293E cells were detected in an
ELISA specific for HA from A/Shanghai/1/2013 (H7N9). (D) Binding of vaccine proteins to B cells (CD19), macrophages (F4/80 CD64), DCs (Lin CD11chi)
divided into conventional DC1 (CD24) and conventional DC2 (CD11b), and T cells (CD3) from BALB/c splenocytes.
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Mice were immunized with plasmids targeting H7 toward either CCR1/3/5 or MHC-II
molecules or with nontargeted control vaccines (Nip-H7 and H7). In addition, a group
was vaccinated with MHCII-H1 to control for specificity (Fig. 3A). To generalize the
effect of APC targeting, parallel experiments were performed in BALB/c mice and the
CB6F1 hybrid strain. Results demonstrated that IgG responses were significantly ele-
vated already the first weeks after vaccination with MHCII-H7 in both BALB/c (Fig. 3B)
and CB6F1 mice (Fig. 3C). The antibody responses after vaccination with Mip1-H7
were only significantly increased above that of the nontargeted controls at week 4
postvaccination for both mouse strains. As expected, MHCII-PR8 did not induce any
antibodies that cross-reacted with influenza H7. The same trends were observed when
the vaccines were delivered intramuscularly (i.m.) in BALB/c (data not shown).
In order to assess the neutralizing antibody response, sera from weeks 2 and 4
postvaccination in BALB/c were examined in a pseudotype-based neutralization assay
against A/FPV/Rostock/1934(H7N1) HA and neuraminidase (NA) pseudotype virus. The
results demonstrated that a single vaccination with MHCII-H7 significantly increased
50% inhibitory concentration (IC50) levels in sera at both 2 and 4 weeks postvaccination
compared to the nontargeted control vaccines (NIP-H7 and H7) (Fig. 3D). Furthermore,
significantly enhanced IC50 levels were observed in sera collected 4 weeks after
vaccination with Mip1-H7, compared to the nontargeted controls. The results for both
MHCII-H7 and Mip1-H7 corresponded to the increases that were observed in
enzyme-linked immunosorbent assay (ELISA; P  0.05, Spearman correlation IC50 and
serum titers) (Fig. 3B and D). When extending the analyses to examinations of IC90
titers, vaccination with MHCII-H7 significantly increased the levels of protective anti-
FIG 2 MHC-II-targeted HA vaccination with or without a multibasic cleavage site. (A) Alignment of the
MBCS in H7 and the deleted corresponding sequence in H7Δ. (B) Schematic illustration depicting the
vaccine monomer with indicated MBCS in HA. The full-length vaccine monomer is 150 kDa and HA2
is 35 kDa, resulting in fragments of 115 and 35 kDa, respectively, under reducing conditions. (C)
Western blot of secreted vaccine proteins (indicated) under reducing conditions in supernatant from
transiently transfected 293E cells. (D) Binding of secreted MHCII-H7 or MHCII-H7Δ proteins in super-
natants from transiently transfected 293E cells detected in an ELISA specific for HA from A/Shanghai/1/
2013 (H7N9). (E) Mice (n  6/group) were vaccinated i.d. with plasmid DNA encoding either MHCII-H7
or MHCII-H7Δ, or NaCl, and IgG in sera measured in ELISA against recombinant HA from influenza
A/Shanghai/1/2013(H7N9) at weeks 1, 2, and 4 postvaccination. *, P  0.05 (two-tailed Mann-Whitney
test).
Andersen et al. Journal of Virology
December 2017 Volume 91 Issue 23 e01340-17 jvi.asm.org 4











bodies compared to nontargeted controls. Taken together, the data demonstrated that
MHCII-H7 is superior at induction of neutralizing antibodies compared to Mip1-H7
and nontargeted controls.
Vaccine induced production of IFN--secreting cells and cytotoxic T lympho-
cytes. Although antibodies may block an influenza infection, T cells can clear already
infected cells. Thus, the different DNA vaccines were assessed for their ability to induce
sustained IFN--secreting cells and cytotoxic T lymphocytes (CTL) after immunization.
Splenocytes were harvested 8 weeks postvaccination and restimulated with recombi-
nant HA from H7N9 influenza. The results demonstrated that mice receiving either
MHCII-H7 or Mip1-H7 induced significantly higher levels of IFN--secreting cells
compared to the nontargeted controls (Fig. 4A). The enhanced induction was specific
for H7, since restimulation with HA from other influenza A subtypes failed to increase
IFN- production. As an additional control, MHCII-H1 increased the levels of IFN--
secreting cells only after stimulation with HA from H1N1 influenza (Fig. 4B).
To further address whether the increase in IFN--secreting cells could be interpreted
as increased CTL activity in vivo, we retrovirally transduced an A20 mouse B lymphoma
cell line to express cytosolic H7 and GFP, or mCherry as a control. At week 5 postvac-
cination, the cell lines were injected into BALB/c mice, and the ratio between green
fluorescent protein (GFP)- and mCherry-positive cells was investigated 16 h later by
FIG 3 Antibody responses after a single DNA vaccination. (A) Schematic illustration of the experiment.
Briefly, BALB/c (n  12/group) or CB6F1 mice (n  6/group) were DNA vaccinated once i.d. with the
indicated vaccine plasmids. Sera were collected up to 4 weeks postvaccination from BALB/c (B) and
CB6F1 (C), and antibody responses were measured by ELISA against recombinant HA from influenza
A/Shanghai/1/2013 (H7N9). *, P  0.05; **, P  0.01 (two-tailed Mann-Whitney test). (D) Sera from BALB/c
from weeks 2 and 4 were pooled by group and assayed in a pseudotype microneutralization assay
against A/FPV/Rostock/1934 (H7N1). Neutralization curves were fitted with GraphPad Prism 6 software,
and the IC50 and IC90 titers were calculated. *, P  0.05; **, P  0.01 (extra sum-of-squares F test).
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flow cytometry. The killing ratios were calculated by comparing the remaining GFP
population to the control population expressing mCherry (Fig. 4C). Both APC-targeted
vaccines induced significant CTL responses, and in correspondence with the enzyme-
linked immunospot assay (ELISPOT) data, CCR1/3/5-targeting induced a higher T-cell
response compared to the MHC-II-targeted vaccine. In sum, the data demonstrated that
targeting of HA to APCs significantly increased the vaccine induced T-cell responses
and that they can participate in protection against an influenza infection.
A single APC-targeted DNA vaccination can protect mice from a lethal influ-
enza challenge. In order to examine whether the APC-targeted vaccines could rapidly
confer protection against influenza, mice were DNA immunized once intradermally (i.d.)
and then challenged with a lethal dose of influenza A/turkey/Italy/3889/1999 (H7N1) 5
weeks after vaccination. Mice that received the APC-targeted vaccines showed signif-
icantly less morbidity compared to the nontargeted controls, and both BALB/c (Fig. 5A),
and CB6F1 mice (Fig. 5B) were fully protected against influenza. In contrast, mice that
received saline or nontargeted controls rapidly lost weight, and 40 to 60% of the mice
receiving the nontargeted control vaccines had to be euthanized within 8 days post-
challenge.
The influenza strain used for challenge has some sequence differences compared to
the vaccine strain. In order to examine protection in a homologous challenge model,
we also immunized mice with HA from A/turkey/Italy/3889/1999 (H7N1) and chal-
lenged them with this strain 5 weeks later (Fig. 5C). Mice receiving APC-targeted
vaccines were fully protected against the lethal influenza challenge, in contrast to the
nontargeted control vaccines. For the heterologous challenge experiments above
(Fig. 5A and B), APC targeting of HA significantly improved protection against the
influenza challenge compared to the nontargeted control vaccines, but we also
observed an increased weight loss in mice receiving MHC-II-targeted HA compared
to the group vaccinated with Mip1a-H7. Here, we observed no significant difference
in weight loss after MHC-II- and CCR1/3/5-targeted vaccination in the homologous
challenge (Fig. 5C).
In order to further examine the differences in protection after vaccination with
MHC-II- and CCR1/3/5-targeted HA, we set up an experiment examining lung pathology
after viral challenge in BALB/c mice. Thus, mice were immunized with HA from
FIG 4 Induction of T cells after a single immunization. BALB/c mice (n  6/group; n  3/group for NaCl
and H1 controls) were DNA vaccinated i.m. with plasmids encoding the indicated vaccines. Spleens were
harvested at 8 weeks postvaccination. Splenocytes were restimulated with recombinant HA from
A/Shanghai/1/2013(H7N9) (A) or HA from either A/Shanghai/1/2013(H7N9), A/Vietnam/1194/
2004(H5N1), or A/Puerto Rico/8/34(H1N1) (B), and the numbers of IFN--secreting cells were evaluated.
(C) BALB/c mice (n  6/group) were vaccinated i.d. with plasmid DNA encoding the indicated vaccines.
After 5 weeks, 5  106 A20 cells expressing cytosolic H7 and GFP and 5  106 A20 cells expressing
cytosolic mCherry were injected i.v. The prevalences of GFP- or mCherry-positive cells were assessed 16
h later, and the killing ratios were calculated. *, P  0.05; **, P  0.01 (two-tailed Mann-Whitney test).
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A/chicken/Italy/13474/1999 (H7N1) and challenged 5 weeks later with A/turkey/Italy/
3889/1999 (H7N1). At day 7 postchallenge, lungs were harvested, sectioned and stained
with hematoxylin and eosin (H&E). Lungs harvested from control mice receiving NaCl
and nontargeted control vaccines displayed histiocytic alveolitis, interstitial pneumonia,
and edema. In contrast, mice receiving APC-targeted vaccines had healthy lungs with
only minor lung pathology (Fig. 5D). Further, we observed that lungs collected from
mice vaccinated with Mip1-H7 showed more cellular infiltration and lung pathology
compared to mice vaccinated with MHCII-H7.
Targeted vaccines induce T-cell responses that contribute to protection against
viral challenge. In order to investigate whether the main mediator of protection was
antibodies or T cells, immunized mice were depleted of CD4 and CD8 T cells just
prior to a lethal influenza challenge (Fig. 6). The depletion was maintained by injections
of CD4- and CD8-depleting antibodies every other day and was determined to have an
efficacy level of 99% (data not shown). T-cell-depleted mice showed no significant
increase in mortality compared to mice receiving isotype matched control antibodies.
This demonstrated that the induced antibodies were protective. However, recovery
after infection was significantly impaired in T-cell-depleted mice, as shown by the
significant differences in morbidity that were observed during the second week after
infection. The experiment highlights the importance of T cells in clearing a heterolo-
gous influenza infection. In conclusion, the APC-targeted vaccination induced both
antibodies and T cells that contribute to protection against influenza.
FIG 5 Viral challenge of DNA-immunized mice. BALB/c mice (n  6 to 12/group) or CB6F1 mice (n  6/group) were vaccinated with
25 g of DNA i.d. and challenged with 20  LD50 of mouse-adapted A/turkey/Italy/3889/1999 (H7N1) at week 5 postvaccination. The
body weight (upper panels) was measured after challenge to assess morbidity, and survival curves (lower panels) are shown for mice
receiving the indicated vaccines from BALB/c mice (A) and CB6F1 mice (B). (C) BALB/c mice were vaccinated with vaccines encoding
the HA antigen A/turkey/Italy/3889/1999 (H7N1) homologous to the challenge strain and challenged at week 5 postvaccination.
Weight curves: *, P  0.05; **, P  0.01 (two-way ANOVA). Survival curves: *, P  0.05; **, P  0.01 (Gehan-Breslow-Wilcoxon test). (D)
Representative micrographs of H&E-stained sections of lungs from each group from the experiment in panel A collected 7 days
postchallenge. Scale bar, 250 m.
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In the event of a pandemic outbreak of HPAIV, a vaccine platform capable of
launching a quick production and response is crucial. It is essential to rapidly induce
protective immunity in the population to limit viral spread and disease. We have here
demonstrated that DNA vaccines targeting HA from HPAIV H7 to APCs in mice
represent a potential vaccine candidate for induction of rapid immunity. Importantly,
the APC-targeted DNA vaccines could mediate protection in mice that were challenged
with a lethal dose of influenza H7N1 virus only 5 weeks after vaccination.
We have here used HA from either A/turkey/Italy/3889/1999 (H7N1) or A/chicken/
Italy/13474/1999 (H7N1) for vaccination, and we observed that both vaccines can
confer protection against a viral challenge with A/turkey/Italy/3889/1999 (H7N1). Thus,
the induced immune responses can to some extent confer heterologous protection
against different H7 strains. Although this cannot at present be generalized to more
H7 strains, we also found that vaccination with HA from A/chicken/Italy/13474/1999
(H7N1) raised neutralizing antibodies against A/FPV/Rostock/1934 (H7N1) in a
pseudotype-based neutralization assay.
In order to further investigate the mechanisms behind protection, mice vaccinated
with Mip1-H7 or MHCII-H7 were injected with depleting antibodies against CD4
and CD8 T cells or isotype-matched control antibodies. After challenge with the H7N1
virus, no significant differences were observed in survival between the T-cell-depleted
mice and the isotype-treated mice. Although this indicated that cross-reactive antibod-
ies contributed to the protection, T-cell-depleted mice showed a significant increase in
morbidity and delayed recovery postchallenge. Presumably, the vaccine induced neu-
tralizing antibodies that could recognize the heterologous virus were below the
limiting threshold necessary to mediate complete sterile protection at the given dose.
In this situation, a recall of a neutralizing memory B-cell repertoire during the first days
of infection likely inhibited ongoing viral infections, but the lack of viral clearance in
already infected cells led to some disease manifestations. This observation held true
both for mice vaccinated with MHCII-H7 and for mice vaccinated with Mip1-H7.
Previously, we have demonstrated that targeting of antigen to MHC-II molecules is
particularly efficient for induction of antibodies, whereas targeting of antigen to
CCR1/3/5 more efficiently will induce T-cell responses (25). After vaccination with
A/chicken/Italy/13474/1999 (H7N1) and challenge with A/turkey/Italy/3889/1999 (H7N1),
we observed that mice vaccinated with Mip1-H7 had a significantly reduced weight loss
FIG 6 Viral challenge of DNA-immunized mice after depletion of T cells. Mice (n  8 to 10/group) were
DNA vaccinated i.d. with the indicated vaccines and then challenged with 20  LD50 A/turkey/Italy/
3889/1999 (H7N1) 5 weeks postvaccination. Two days prior to challenge—and every other day until
completion of the experiment—mice were injected i.p. with either CD4 and CD8 depleting MAbs or
isotype-matched MAbs. Starting at the day of challenge (D0), weight was monitored in mice vaccinated
with Mip1-H7 (A) or MHCII-H7 (B). *, P  0.05; **, P  0.01 (two-way ANOVA). (C) Survival curves for
mice in panels A and B. *, P  0.05; **, P  0.01 (Gehan-Breslow-Wilcoxon test).
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compared to MHCII-H7. In contrast, we found no significant difference in weight loss
between mice vaccinated with MHCII-H7 or Mip1-H7 when HA from the homologous
strain was used. T cells have an increased potential for mediating cross-protection
within variations of antigenic drift (34), since T-cell epitopes are more conserved across
different subtypes (35). It is therefore likely that increased numbers of IFN--secreting
T cells and the slight increased CTL response after Mip1-H7 vaccination, compared to
MHCII-H7, can account for the difference in weight loss observed after heterologous
challenge. Furthermore, the antibody response after Mip1-targeted vaccine delivery is
dominated by IgG2a (25). Nonneutralizing H7-specific IgG2a antibodies have also been
demonstrated to be protective in mice (36, 37). Antigen-specific antibodies of the IgG2a
isotype efficiently induce Fc-receptor-mediated effector functions such as antibody-
dependent cell-mediated cytotoxicity (ADCC) (38, 39), complement-dependent cyto-
toxicity (40, 41), or antibody-dependent cell phagocytosis (42, 43). In addition, ADCC
triggering antibodies have been shown to be cross-reactive (44) and might be of
particular importance in a pandemic setting (44, 45). In summary, both MHC-II and
CCR1/3/5 targeting vaccines induced humoral and cellular responses that contributed
to the mode of the observed protection.
Targeting of H7 to APCs consistently increased immune responses, compared to
nontargeted controls. Of note, a direct ligation between antigen and targeting unit has
been found a prerequisite for efficient induction of immunity (46). It is possible that
binding of an APC-targeted vaccine to an APC will improve access to antigenic epitopes
and as such promote more efficient binding to B-cell receptors. A stronger and more
specific ligation of DCs or B cells might drive an accelerated formation of germinal
centers with subsequent isotype switching and affinity maturation. Furthermore, the
APC-targeted vaccine could bridge APCs and B cells in a synapse that promotes
efficient and mutual activation (47, 48). Furthermore, a synapse formation between an
APC and a B cell could lead to B cells sampling antigen from the top, i.e., the head
region of HA. This might lead to selection B cells recognizing more neutralizing
epitopes in HA resulting in an antibody repertoire with highly neutralizing capacity, as
observed with the MHC-II-targeted vaccine.
Our data have clearly demonstrated the benefit of targeting antigen to APCs,
particularly when the aim is to induce rapid immune responses to limit the outbreak of
pandemic influenza. Previous studies have demonstrated that the immune potentiating
effect when targeting to APCs is particularly prominent for weak antigens (28, 32). In
contrast, HA from HPAIV H7 is immunogenic in mice, and vaccination with the H7
antigen alone was able to induce modest IgG titers over time. It is possible that avian
HAs have increased immunogenicity compared to human HAs due to differences in
glycosylation patterns that would stimulate production of immunostimulatory agents
in DCs (49). In addition, inactivated influenza viruses with an 2,3 preference for sialic
acid receptors have been shown to induce higher levels of proinflammatory cytokines
in human DCs (18). Thus, HA from HPAIV might trigger an innate immune response that
translates into activation of adaptive immunity in mice. However, the antibody levels
observed after immunization with nontargeted controls developed significantly more
slowly than for the APC-targeted vaccines. Furthermore, the nontargeted controls do
not enhance immune responses to the same extent as the APC-targeted vaccines and,
most importantly, only APC-targeted vaccines could induce protective immunity, after
a single vaccination, toward a lethal challenge with influenza virus.
When using conventional vaccine manufacture for selected avian influenza strains,
removal of the MBCS and exchange of certain internal genes is required (4). However,
removal of the MBCS can render the virus low pathogenic and poorly immunogenic,
compromising vaccine efficacy with obvious implications for vaccine design against
pandemic outbreaks (17, 50). Here, we also found that deletion of the MBCS was
associated with reduced immunogenicity, which again highlights a benefit of using
DNA-based vaccines. Ubiquitous proteases will cleave H7 in the vaccine molecules in
vivo. Cleavage of HA in the APC-targeted vaccine molecule results in efficient presen-
tation of the native head region in HA1. Vaccines expressed with uncleaved HA0 might
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lack some of the essential structural epitopes in HA1 or the HA1-HA2 interface. The
majority of protective antibodies bind to the globular head domain of HA. Thus, the
cleaved H7 format could more efficiently present epitopes from native HA1, potentially
resulting in a more stringent selection of B cells with neutralizing capacity. This effect
is probably tissue and species dependent (23, 51), but it is a general benefit from DNA
vaccines.
We have here demonstrated that a single DNA vaccination with APC-targeted H7
can confer protection against H7 influenza in mice. No other vaccine format can at
present compete with the speed of production and deployment that is possible for
DNA vaccines. For prophylactic mass vaccinations, DNA vaccines can be delivered
without adjuvant to the dermis by noninvasive needle-free jet delivery systems (26, 52).
Ideally, the DNA vaccine should be tailored to precisely match an emerging pandemic
strain, which is also a feasible strategy given the short time in which DNA vaccines can
be mass produced. The rapid induction of protective antibodies observed when
targeting H7 to MHC-II molecules highlights this receptor as particularly interesting for
construction of pandemic DNA vaccines. For broader protection, it could be beneficial
to target the H7 to chemokine receptors. In summary, we have here demonstrated that
DNA delivery of an APC-targeted vaccine could greatly aid the control of an unexpected
pandemic threat.
MATERIALS AND METHODS
Molecular cloning. The HA genes from A/chicken/Italy/13474/1999 (H7N1) (aa19-536) and A/turkey/
Italy/3889/1999 (H7N1) (aa19-536) were ordered with flanking SfiI sites (GenScript, Piscataway, NJ) and
cloned into the previously described hCMV-based pLNOH2 vaccine vectors equipped with targeting units
consisting of either a single-chain-variable fragment (scFv) specific for MHC-II (I-Ed) (32), an scFv specific
for the hapten 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) (nontargeted control) (32), or the mac-
rophage inflammatory protein 1 (Mip-1) (25, 28). In another vaccine construct, the multibasic cleavage
site (aa340-343) was removed from HA (H7Δ), and the gene was cloned into a vaccine vector with an
MHC-II-specific scFv. In addition, a vaccine construct encoding only HA was constructed by introduction
of an upstream BsmI restriction site with primers the 5=-GGTGTGCATTCCGGCCTCGGTG and 3=-GTGGAT
CCTCTAGAGTCGACGGACCGGC (the BsmI site and the start of the SfiI site are underlined).
Assessment of in vitro expressed vaccine proteins. An influenza A H7N9 (A/Shanghai/1/2013)
hemagglutinin ELISA pair set (SEK40104; Sino Biological, Inc., North Wales, PA) was used. Briefly, ELISA
plates (Costar 3590; Corning, Corning, NY) were coated with 0.5 g/ml rabbit anti-HA monoclonal
antibody (MAb), blocked with 1% bovine serum albumin (BSA), and incubated with supernatants
from 293E cells transfected with 1-g vaccine plasmids and 2 g of polyethylenimine (PEI). Vaccine
proteins were detected with horseradish peroxidase-conjugated anti-HA pAb (1 g/ml) and 3,3=,5,5=-
tetramethylbenzidine (TMB) substrate (CL07; Merck Millipore, San Diego, CA). The reaction was stopped
after 20 min of incubation with an equal volume of 0.5 M H2SO4, and the plates were read at 450 nm with
a Tecan reader (Tecan, Switzerland) using Magellan v5.03 software.
Vaccine proteins were produced by transient transfection of 293E cells with PEI. Constructs contain-
ing the CH3 domain were purified on a CaptureSelect FcXL affinity column (catalog no. 194328005; Life
Technologies, Naarden, The Netherlands). Splenocytes were harvested from BALB/c mice, and single cell
suspensions were FcR blocked by incubation with 30% heat-inactivated rat serum and stained with
purified vaccine proteins, CD3-VF450 (catalog no. 75-0032; Tonbo Biosciences, San Diego, CA), CD19-FITC
(catalog no. 35-0193; Tonbo Biosciences), CD11b-PerCP/Cy5.5 (catalog no. 65-0112; Tonbo Biosciences),
CD11c-PE/Cy7 (catalog no. 117318; BioLegend, San Diego, CA), F4/80-AF700 (catalog no. 123130;
BioLegend), and CD64-APC (catalog no. 139306; BioLegend), followed by hCH3-PE (catalog no. 409304,
BioLegend). Cells were analyzed on an Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham,
MA) and FlowJo software.
Western blotting. Vaccine plasmids were transiently transfected into 293E cells as described above.
Supernatants were up-concentrated (VivaSpin 500, MWCO 10000; Sartorius, Gottingen, Germany) and
denatured in sodium dodecyl sulfate sample buffer at 95°C for 5 min. The samples were then run on a
Bolt 4 to 12% Bis-Tris Plus gel (NW04122BOX; Novex, Carlsbad, CA), blotted onto a polyvinylidene
difluoride (PVDF) membrane (catalog no. IB24001, iBlot transfer stack; Invitrogen, Kiryat Shmona, Israel),
blocked in 2% skimmed milk, and detected by using monoclonal (Fig. 1) or polyclonal (Fig. 2) rabbit H7
antibodies (SEK40104; Sino Biological). Next, the membrane was incubated with polyclonal goat anti-
rabbit IgG conjugated to alkaline phosphatase (ALP; A3687; Sigma-Aldrich) and developed with the
BCIP/NBT-Purple Liquid substrate system for membranes (B3679; Sigma-Aldrich).
Mice and cell lines. Cell work was performed with human embryonic kidney 293E cells purchased
from the American Type Culture Collection (ATCC; Manassas, VA, USA). Six- to eight-week-old female
BALB/c or CB6F1 mice (Janvier, le Genest-Saint-Isle, France) were used in all experiments. The animals
were housed under minimal disease conditions, and all animal experiments were preapproved by the
Norwegian Animal Research Authority.
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Vaccination. Mice were anesthetized (0.1 mg/10 g [body weight] with a cocktail composed of Zoletil
Forte [250 mg/ml; Virbac France], Rompun [20 mg/ml; Bayer Animal Health GmbH], and fentanyl [50
g/ml; Actavis, Germany]) by intraperitoneal (i.p.) injection. For i.d. delivery of vaccines, the lower back
region of each mouse was shaved, and 12.5 g of plasmid in a 25-l volume was injected at two sites
(total DNA/mouse, 25 g), immediately followed by skin electroporation (DermaVax; Cellectis, Paris,
France). For i.m. delivery of vaccines, mice were shaved on each leg, and 6.25 g of DNA was injected
in a 50-l volume into each quadriceps femoris (total DNA/mouse, 12.5 g). Immediately after injection,
electrical pulses were applied at the injection site (Elgen; Inovio Biomedical Co., Blue Bell, PA). All DNA
vaccines were purified by using an EndoFree Plasmid Mega kit (catalog no. 12381; Qiagen, Hilden,
Germany) and dissolved in sterile injection fluid (0.9% NaCl).
Serum ELISA. Blood was harvested by puncture of the saphenous vein, and sera were isolated by
centrifugation. ELISA plates (Costar 3590) were coated with 0.5 g/ml recombinant HA [A/Shanghai/1/
2013 (H7N9)] (40104-V08B; Sino Biological), blocked with 1% BSA, and incubated with serially diluted
serum samples assayed individually (n  6 to 12/group). HA-specific antibodies were detected with
alkaline phosphatase conjugated goat anti-mouse IgG (A1418; Sigma-Aldrich), developed with phospha-
tase substrate (P4744; Sigma-Aldrich) and analyzed as previously described. For all serum ELISAs, titers
were determined as the last serum dilution with an optical density at 405 nm above background (the
mean absorbance from NaCl-vaccinated mice added five times the standard error of the mean for the
group).
Pseudotype-based neutralizing assay. Pseudotyped virus was prepared and quantified as previ-
ously reported (53). Briefly, 3  103 MDCK cells were seeded in each well of a 96-well culture plate
(Corning) and incubated overnight at 37°C in 5% CO2 and saturated humidity. Then, serially diluted
serum samples, pooled by group, that had been preincubated with HA and NA pseudotypes from
A/FPV/Rostock/1934 (H7N1) (2,000 to 200,000 relative luciferase activity [RLA]) at 37°C in 5% CO2 and
saturated humidity for 1 h were added to the cells for 72 h of incubation at 37°C in 5% CO2 and saturated
humidity. The RLA values were measured by a BrightGlo luciferase assay according to the manufacturer’s
instructions (Promega, Madison, WI). The percent inhibition was calculated as follows: (RLA in pseu-
dotypes and medium control  RLA in pseudotypes and immune serum at a given dilution)/RLA in
pseudotypes and medium control. The data were fitted to a sigmoidal dose-response curve using
GraphPad Prism 6 software, and IC50 and IC90 values were determined from those data sets.
ELISPOT assay. Mouse IFN- ELISPOT Plus plates (3321-4APT; Mabtech, Nacka Strand, Sweden) were
blocked with RPMI plus 10% fetal calf serum for 2 h at 37°C in 5% CO2. Mouse spleens were harvested
at 8 weeks postinfection, and single cell suspensions were prepared with a gentleMACS dissociator
(Milteny Biotec, Bergisch Gladbach, Germany), followed by incubation in ACT lysis buffer for 5 min on ice.
Next, 0.5  106 cells were seeded per well, and cells were stimulated with either medium (negative
control), ConA (1 g/ml, positive control), or 10 g/ml recombinant HA from either A/Shanghai/1/2013
(H7N9), or A/Puerto Rico/8/1934 (H1N1), or A/Vietnam/1194/2004 (H5N1) (40104-V08B, 11684-V08H, and
11062-V08H1, respectively; Sino Biological). Plates were incubated for 20 h at 37°C in 5% CO2 before
incubation with the detection antibody (3321-4APT; Mabtech) and development with the BCIP/NBT-
Purple liquid substrate system for membranes (B3679; Sigma-Aldrich). Plates were analyzed with the
CTL-ImmunoSpot analyzer (CTL, Shaker Heights, OH).
In vivo killing assay. A20 cells expressing cytosolic H7 and GFP, as well as control cells expressing
mCherry, were created by retroviral transduction, followed by selection of highly expressing cells by
fluorescence-activated cell sorting. H7 GFP cells and mCherry cells (5  106; 1:1) were injected intrave-
nously (i.v.) into BALB/c mice, and the prevalence of GFP-positive and mCherry-positive cells in the spleen
were analyzed 16 h later in an Attune NxT flow cytometer (Thermo Fisher Scientific, Waltham, MA) using
FlowJo software. Killing ratios were calculated by defining the average ratio between the two cell lines
in the NaCl group as 0% killing and finding no H7 GFP cells as 100% killing.
Viral challenge. Mice were anesthetized as described previously and inoculated with 20  LD50
mouse-adapted A/turkey/Italy/3889/1999 (H7N1) in 10 l/nostril. Mice were monitored for weight loss,
and mice that lost 20% of the original body weight were euthanized by cervical dislocation.
H&E staining of lung sections. Formalin-fixed lungs were embedded in paraffin, sectioned, and
stained with H&E. Sections were mounted using Dako toluene-free mounting medium (CS705; Dako,
Santa Clara, CA). Micrographs of tissue sections were collected using Nikon Eclipse Ti-S microscope
(Nikon Corporation, Tokyo, Japan), and a 10/0.30 objective lens.
T-cell depletion. Mice (n  10/n  8 [NaCl group]) were vaccinated once i.d. as previously described.
Two days prior to challenge and then every other day until completion of the experiment, 200 g of
anti-CD4 MAb (GK1.5; ATCC) and 200 g of anti-CD8 MAb (TIB105; ATCC), or control MAbs (200 g of
SRF8-B6 and 200 g of Y13-238) (23), were injected i.p. into the mice. At the end of the experiment, the
spleens were harvested to assess T-cell depletion. Briefly, single cell suspensions were prepared, and cells
stained with fluorescein isothiocyanate-conjugated anti-mouse CD3e (catalog no. 35-0031; Tonbo Bio-
sciences), PerCP-Cy5.5-conjugated rat anti-mouse CD45R (catalog no. 552771; BD Pharmingen), APC-
conjugated rat anti-mouse CD4 (catalog no. 1540-11; Southern Biotech Associates, Birmingham, AL), and
PE-conjugated rat anti-mouse CD8a (553033; BD Pharmingen). For background assessments, the follow-
ing isotype controls were used: APC-conjugated rat IgG2b (catalog no. 0118-11; Southern Biotech
Associates, Birmingham, AL) and PE-conjugated rat IgG2a (catalog no. 553930; BD Pharmingen). The data
were analyzed with FlowJo 10.2 software. Representative flow panels of the stained splenocytes are
shown in Fig. S3 in the supplemental material. The degree of depletion was 99%.
Statistical analysis. P values represent exact values calculated by unpaired nonparametric two-tailed
Mann-Whitney tests. Data treated with sigmoidal fitting software are represented with P values from the
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comparison by the extra sum-of-squares F test to determine significance of the inhibitory concentration
(IC) levels. Correlation was computed using nonparametric Spearman correlation and represented with
a two-tailed P value. Weight curves were analyzed with two-way analysis of variance (ANOVA), and
survival curves were analyzed with the Gehan-Breslow-Wilcoxon test. All analyses were performed using
GraphPad Prism 6 software.
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